Jeff Fairman, VP, Research at Vaxcyte, Inc. (PCVX), sold 10,183 shares at $26.54 ($270K) on 2022-09-06, disclosed to the SEC on 2022-09-07.
Open-market sale of $270k PCVX by VP, Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.38 | 519 | $14K | 5.1% |
| 2 | $26.54 | 4,664 | $124K | 45.8% |
| 3 | $26.54 | 4,664 | $124K | 45.8% |
| 4 | $27.14 | 336 | $9K | 3.4% |
| Total | $26.55 avg | 10,183 | $270K | 100% |
| Filing → |
| PCVX | SELL | 2022-08-05 | $384K | — | Filing → |
| PCVX | SELL | 2022-05-24 | $105K | — | Filing → |
| PCVX | SELL | 2022-05-09 | $23K | — | Filing → |